PT-819

N/A

Report date: 2026/03/19 17:22:24

Base Information

Drug NamePT-819

Drug Alias NamePT-819

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionDelta-like protein 3 inhibitorsT cell surface glycoprotein CD3 stimulants

TargetsDelta-like protein 3T cell surface glycoprotein CD3

Therapy Area/IndicationsSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPhanes Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesPhanes Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung Carcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A